Cannabix and UBC are operating collectively to create marijuana breathalyzer technologies for a variety of markets
VANCOUVER, British Columbia, Sept. 23, 2019 (GLOBE NEWSWIRE) — Cannabix Technologies Inc. (CSE:BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of the Cannabix Marijuana Breathalyzer is pleased to report that the Enterprise has entered into an exclusive license agreement with the University of British Columbia (“UBC”) to use and commercialize specific technologies for the detection of volatile organic compounds for testing (to be applied for marijuana breathalyzer purposes) owned by UBC created by Dr. Mina Hoofar and her group of researchers at the UBC Okanagan College of Engineering. The patent pending UBC technologies recognized as a “THC Breath Analyzer” (“THCBA”) incorporates hugely sensitive microfluidic sensors that can be manufactured at somewhat low expense. This exclusive technologies license will let for Cannabix to provide a complementary low-expense transportable breathalyzer device that would be ideally suited for workplace, parental and private use testing. Cannabix’s sophisticated “FAIMS” (field asymmetric waveform ion mobility spectrometry) primarily based marijuana breathalyzer program will be mainly focussed on roadside testing with law enforcement and toxicology lab confirmation. UBC is establishing the THCBA on an accelerated pace and Cannabix anticipates that a breathalyzer device is anticipated to be out there for expanded testing this fall/winter. Important improvement function has been achieved on the THCBA by UBC and pictures of the of the THCBA transportable device (below improvement) can be viewed at cannabixtechnologies.com (and are integrated in this press release).
The Enterprise believes that the skilled requirements of law enforcement customers (use at police stations and court acceptance) will probably differ from the requirements of employers, and civilian customers of such devices. Specificity of use, pricing, ruggedization, disposables and calibration needs will all be aspects in delivering a number of breathalyzer merchandise that meet the requirements of certain clients. The THCBA technologies will provide a somewhat low-expense option to the skilled grade selectivity and sensitivity provided by the Cannabix FAIMS marijuana breathalyzer. Cannabix’s FAIMS device makes it possible for for mass spectrometry (MS) laboratory confirmation with its exclusive capacity to couple straight to MS. With each devices becoming created by Cannabix, the Enterprise aims to substantially expand its possible base of clients for its merchandise and solutions.
Rav Mlait, CEO of Cannabix stated, “We are exceptionally excited about this chance to add this complementary technologies license to our solution portfolio. The joint UBC-Cannabix collaboration on this low-expense marijuana breath testing technologies will facilitate our method to greater segment industry possibilities with a number of devices. The marijuana breathalyzer technologies universe is in its early stages, and it is strategically critical for Cannabix to commercialize technologies that can bolster its capacity to provide a variety of merchandise to meet the requirements of various client segments. We think that diversifying our technologies holdings will be critical as regulators worldwide start to comprehend the various forms of cannabis breathalyzer/detection technologies that are emerging. We want to be properly ready to meet evolving evidentiary regulatory requirements for drug breath testing technologies.”
Dr. Mina Hoofar stated, “It is generally thrilling to see our study, that originates on the Okanagan campus of UBC, extend to the subsequent stage of improvement. We are thrilled that via this collaboration, devices will quickly enter the industry for self-monitoring and usage as a marijuana breathalyzer. This collaboration will bring our findings to industry supplying customers with very affordable, transportable, rapid and precise devices. Collaborating with Cannabix signifies that we can leverage their experience in marketing and advertising and implementation, bringing the THC Breath Analyzer a single step closer to getting into the industry. We appear forward to future collaborations with Cannabix as we continue to strive for innovation in the fields of micro-fluidics and bio-marker evaluation.”
The Enterprise also reports granting two million incentive stock alternatives exercisable at $.80 cents per share for 5 years to officers and directors and two years for consultants.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a leader in marijuana breathalyzer improvement for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing transportable tools to industry to improve detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in numerous jurisdictions globally. Cannabix is operating to create drug-testing devices that will detect THC- the psychoactive element of marijuana that causes intoxication- applying breath samples. In specific, Cannabix is focused on establishing breath testing devices for detection of current use of THC, in contrast to urine testing for THC metabolite that demands an invasive collection and reflects usage, days or even weeks earlier. The devices will also be valuable for other sensible applications such as testing personnel in the workplace exactly where impairment by THC can be hazardous and for private use testing.
We seek Protected Harbor.
On behalf of the Board of Directors
Cannabix Technologies Inc.
For additional facts, make contact with the Enterprise at [email protected]
The CSE has not reviewed and does not accept duty for the adequacy or accuracy of this release.
Cautionary Statement Relating to Forward-Seeking Statements
This press release consists of forward-hunting facts that entails numerous dangers and uncertainties relating to future events. Such forward-hunting facts can consist of without having limitation statements primarily based on present expectations involving a quantity of dangers and uncertainties and are not guarantees of future functionality of the Enterprise, such as final improvement of a industrial or prototype solution(s), productive trial or pilot of business technologies, no assurance that industrial sales of any sort in fact materialize no assurance the Enterprise will have adequate funds to total solution improvement. There are a lot of dangers and uncertainties that could lead to actual final results and the Company’s plans and objectives to differ materially from these expressed in the forward-hunting facts, like: (i) adverse industry circumstances (ii) dangers relating to protection of proprietary technologies (iii) the capacity of the Enterprise to total financings (iv) the capacity of the Enterprise to create and industry its future solution and (v) dangers relating to government regulation, managing and preserving development, the impact of adverse publicity, litigation, competitors and other aspects which may perhaps be identified from time to time in the Company’s public announcements and filings. There is no assurance that the marijuana breathalyzer business enterprise will deliver any advantage to the Enterprise, and no assurance that any proposed new merchandise will be constructed or proceed. There is no assurance that current “patent pending” technologies licensed by the Enterprise will obtain patent status by regulatory authorities. The Enterprise is not presently promoting industrial breathalyzers. Actual final results and future events could differ materially from these anticipated in such facts. These and all subsequent written and oral forward-hunting facts are primarily based on estimates and opinions of management on the dates they are produced and are expressly certified in their entirety by this notice. Except as essential by law, the Enterprise does not intend to update these forward-hunting statements.
Photographs accompanying this announcement are out there at: